CytomX Therapeutics Inc.

Clinical-stage oncology company developing conditionally activated therapeutics using its proprietary Probody platform, which masks therapeutic activity until the drug reaches the tumor microenvironment. Lead programs include CX-2051, an EpCAM-targeting ADC in Phase 1 for colorectal cancer, and CX-2029, a CD71-targeting ADC partnered with AbbVie.